Literature DB >> 18199897

Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.

Gilbert Lefèvre1, Françoise Pommier, Greg Sedek, Mark Allison, Hsun-Lun Aaron Huang, Beate Kiese, Yu-Yun Ho, Silke Appel-Dingemanse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18199897     DOI： 10.1177/0091270007312154

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  13 in total

Review 1.  Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

2.  Absolute bioavailability and safety of a novel rivastigmine nasal spray in healthy elderly individuals.

Authors:  Timothy M Morgan; Bob Soh
Journal:  Br J Clin Pharmacol       Date:  2016-10-26       Impact factor: 4.335

Review 3.  Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.

Authors:  Sohita Dhillon
Journal:  Drugs Aging       Date:  2011-11-01       Impact factor: 3.923

Review 4.  An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine.

Authors:  Rita Khoury; Jayashree Rajamanickam; George T Grossberg
Journal:  Ther Adv Drug Saf       Date:  2018-01-08

5.  Development and validation of a spectrofluorimetric method for the estimation of rivastigmine in formulations.

Authors:  R Kapil; S Dhawan; Bhupinder Singh
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

Review 6.  Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease.

Authors:  Nazem Bassil; George T Grossberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

7.  Drug Delivery and Transport into the Central Circulation: An Example of Zero-Order In vivo Absorption of Rotigotine from a Transdermal Patch Formulation.

Authors:  Willi Cawello; Marina Braun; Jens-Otto Andreas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-08       Impact factor: 2.441

8.  A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease.

Authors:  Yu Nakamura; Yukimichi Imai; Masahiro Shigeta; Ana Graf; Toru Shirahase; Hyosung Kim; Akifumi Fujii; Joji Mori; Akira Homma
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2011-06-24

Review 9.  Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.

Authors:  A Kurz; M Farlow; G Lefèvre
Journal:  Int J Clin Pract       Date:  2009-05       Impact factor: 2.503

10.  Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer's Disease.

Authors:  Gilbert Lefèvre; Francesca Callegari; Sandro Gsteiger; Yuan Xiong
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.